Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database
Qin Zhou, Zhiqiang Du, Kankan Qu, et al.
Asian Journal of Psychiatry (2023) Vol. 90, pp. 103828-103828
Closed Access | Times Cited: 22

Showing 22 citing articles:

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
Fan Zou, Zhiwei Cui, Siyu Lou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 40
A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
Fan Zou, Chengyu Zhu, Siyu Lou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Exploring adverse events of Vilazodone: evidence from the FAERS database
Ying Jiang, Yucai Qu, Zhiqiang Du, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database
Jun Gu, Yucai Qu, Yüan Shen, et al.
Journal of Affective Disorders (2024) Vol. 362, pp. 742-748
Closed Access | Times Cited: 5
Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
Qun Xu, Jing Zhang, Weihong Tang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
Xi-Feng Wang, Luri Bao, Ta‐la Hu, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
Yongfu Song, Zhuang Wang, Na Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Analysis and mining of Dupilumab adverse events based on FAERS database
Gao Hui, Liqiang Cao, Chengying Liu
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The real-world pharmacovigilance study based on the FAERS database analyzed the adverse drug events associated with hydroxychloroquine
Shiwei Yuan, Yuan Yongchang, Lin Weifeng, et al.
Research Square (Research Square) (2025)
Closed Access
Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis
Yongfei Yu, Kaiyu Zhang, J.M. Gao, et al.
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0320585-e0320585
Open Access
Assessing the safety of bedaquiline: insight from adverse event reporting system analysis
Jiaqiang Wu, Pan Hong, Li Shen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database
Ying Jiang, Yüan Shen, Qin Zhou, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Association between atorvastatin and erectile dysfunction: a comprehensive analysis incorporating real-world pharmacovigilance and Mendelian randomization
Kaiqin Chen, Hesen Huang, Yongtai Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports
Qi Wang, Qin Zhou, Zhiqiang Du, et al.
Journal of Affective Disorders (2024) Vol. 362, pp. 552-559
Closed Access | Times Cited: 2
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database
Ying Jiang, Yusi Cheng, Z Du, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 6, pp. 567-578
Closed Access | Times Cited: 1
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database
Zicheng Yu, Haibin Zhu, Xiaolan Liao
Expert Opinion on Drug Safety (2024), pp. 1-7
Closed Access | Times Cited: 1
Efficiency and safety of cannabinoid medical use: an analysis of discussions and observed trends on Instagram
Olena Litvinova, Bikash Baral, Thomas Wochele‐Thoma, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 1
Exploring the Relationship Between Atorvastatin and Memory Loss: A Comprehensive Analysis Integrating Real-World Pharmacovigilance and Mendelian Randomization
Kaiqin Chen, Yongtai Chen, Hesen Huang
Drugs in R&D (2024) Vol. 24, Iss. 2, pp. 317-329
Open Access
Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone
Youqi Huang, Hongjin Gao, Yuze Lin, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Adverse events associated with Tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system
Zhenyu Mao, Yuchen Huang, Xiaoyan Zhu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-10
Open Access
Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
Yanjun Lu, Qian Xu, Sixi Zhu
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
Pan Hong, Xiang Shi, Yiguo Jiang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Page 1

Scroll to top